ESC Congress Barcelona 2017 Highlights – Preparing Cardiovascular Medicine for the Digital Era - Verdict Medical Devices
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

ESC Congress Barcelona 2017 Highlights – Preparing Cardiovascular Medicine for the Digital Era

30 Aug 2017 (Last Updated November 22nd, 2018 11:18)

While covering an expansive number of cardiovascular (CV) indications, this year’s European Society of Cardiology (ESC) Conference in Barcelona had a particular focus on digital health.

ESC Congress Barcelona 2017 Highlights – Preparing Cardiovascular Medicine for the Digital Era

While covering an expansive number of cardiovascular (CV) indications, this year’s European Society of Cardiology (ESC) Conference in Barcelona had a particular focus on digital health.

During the inaugural keynote address on opening day, professor of genomics at the Scripps Research Institute  Dr. Eric Topol highlighted the need for the field of cardiology to adopt technology that has the potential to improve CV outcomes.

Many startup companies presented wearable medical devices and portable gadgets that wirelessly transmit collected medical data to mobile devices.

Telehealth device company based in Barcelona i-Cardio presented a personal and portable electrocardiogram (ECG) system that captures ECG data and transmits it to a patient’s smart phone device via Bluetooth.

Another startup company based in Barcelona LifeVit presented a mobile app that centralises data collected from a wide variety of wearable devices, including scales, smart watches, pill bracelets, and thermometers, on to a single platform.

A common aspect among the products presented was that if the data on a monitoring device contained an irregularity such as atrial fibrillation, sinoatrial block, or sinus arrhythmia, the patient’s physician would be alerted through a corresponding mobile app.

While collected digital medical data allows physicians to diagnose cardiac conditions such as coronary artery disease (CAD), rheumatic heard disease (RHD), and heart failure (HF) more quickly, issues surrounding cybersecurity have arisen. Professor emeritus of cardiovascular medicine at Stanford University Dr. Peter Fitzgerald alluded to this during his presentation.

According to Fitzgerald: “There is always a dark side to these innovative edges. There is a massive acceleration of hacks. Medical records are stolen and pacemakers are turned off.

"We have to get better at understanding the pacemaker and the internet protocol (IP) address it sits on when it is in the hospital. Once they get out of the hospital and into the Internet of Things (IOT) environment, that is when these things need to really be tracked.”

Chief privacy and information cyber security officer for Clalit Health Services Dr. Itzik Kochav noted during his lecture on cybersecurity and digital privacy in CV medicine that there are approximately eight billion IP addresses in the world that are used by regular citizens, as well as malicious parties such as hackers and terrorists.

Wireless implantable medical devices that transmit data will need an extra layer of protection from cyberspace to protect patients and data from hackers.

Fitzgerald also added that data such as heart rate variability, blood pressure, and pulmonary status need “to be characterised and integrated into our healthcare system” and that “sensors are only good if there is a service provided by it and ultimately a solution where we can collect the analytics behind it.”

He concluded that “hospitals will decentralise and…care will centralise in the community for preventative, urgent, and chronic care in the future.

“The action of healthcare will be defined by a computer, and the action will be implemented by physicians.”

It will be exciting to see how digital health will impact the field of cardiology over the next fifteen years.

The advances in CV diagnostics will make it much easier for physicians to diagnose PAH patients when they are in World Health Organization Functional Class (WHO FC) I or II instead of when they have already progressed to FC III or IV. Early diagnosis will allow patients to receive treatment early, before the disease manifests any further.